">
Equity Investment
Home Business >Equity Investment >Oriza Horizon
Oriza Horizon

Oriza Horizon is a professional early-stage equity investment platform of Oriza Holdings.

As an early project management team of Oriza Holdings, Oriza Horizon focuses on investing early-stage and growth-stage start-ups in the fields of Healthcare and TMT. It currently has subsidiaries or offices in Suzhou, Shanghai, Hangzhou, Guangzhou, Nanjing and Beijing, to discover and cultivate high quality projects in those cities and surrounding areas. After development for more than 10 years, Oriza Horizon has summarized a set of experiences in early project evaluation, project risk control, project cultivating and value-added services. Meanwhile it has accumulated rich industrial and financial resources, and developed and experienced professional investment team.

Oriza Horizon manages six funds of about 3 billion Chinese Yuan, consisting of VC fund as well regional angel funds. The investment style of Oriza Horizon emphasizes on early stage, technology and commitment. Oriza Horizon has a good reputation among early high-tech start-ups. Oriza Horizon has a professional investment team in the field of healthcare with rich experience and resources. As of the end of September 2017, Oriza Horizon has invested and managed over 70 innovative biotech and medical device companies, including Ascentagepharma, CStone Pharmaceuticals, Innovent Biologics, EpimAbBiotherapeutics, Kintor Pharmaceuticals, and Tenorx Pharma, etc.. Moreover, Oriza Horizon has invested and managed over 100 TMT start-ups, including Jingchi、cambricon、top one、BR-Robot、TZTEK、linkplay、DTWave、360zebra、biyao.com、alsco、and 24tidy.

Partner


XML 地图 | Sitemap 地图